BFC
HZNP

Bedel Financial Consulting’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Bedel Financial Consulting’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-44
Closed -$1K – 975
2020
Q1 		$1K Buy
+44
New +$1.49K ﹤0.01% 793

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bedel Financial Consulting's HZNP Position: Q2 2020 in Review

Bedel Financial Consulting sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2020, closing a stake of 44 shares — an estimated $1K sold.

Bedel Financial Consulting first reported a position in HZNP in Q1 2020 and held it in 1 quarter. The position peaked at $1K in Q1 2020. 354 funds tracked by Wall St. Rank hold HZNP as of Q2 2020.

  • Bedel Financial Consulting reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2020 after selling out during the quarter.
  • Bedel Financial Consulting sold 44 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2020, an estimated $1K.
  • Bedel Financial Consulting first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2020 and held it in 1 quarter.
  • Bedel Financial Consulting's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1K in Q1 2020.
  • 354 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2020.

Based on Bedel Financial Consulting's 13F filing for Q2 2020, filed 14 Jul 2020.